What Researchers Did
Researchers conducted a randomized controlled trial comparing antiseptic dressings, hyperbaric oxygen therapy, and recombinant human platelet derived growth factor in 60 patients with grade III and IV diabetic foot ulcers.
What They Found
Complete wound contraction showed a significant difference between groups (p=0.0348), but healing time (p=0.6534) and ulcer size (p=0.0593) were not significantly different. Recombinant human platelet derived growth factor (rhPDGF) was found to be safe, effective, and easy to apply, with comparable results to hyperbaric oxygen therapy but at a lower cost.
What This Means for Canadian Patients
Canadian patients with severe diabetic foot ulcers might benefit from recombinant human platelet derived growth factor (rhPDGF) as a safe and effective treatment option. This therapy could potentially offer a more affordable alternative to hyperbaric oxygen therapy while achieving similar wound contraction outcomes.
Canadian Relevance
This study has no direct Canadian connection as it was conducted outside of Canada.
Study Limitations
A limitation of this study is its relatively small sample size of 60 patients, which may limit the generalizability of the findings.